Eli Lilly & Co, a leading pharmaceutical company specializing in human pharmaceutical products, has released its 2025 10-K report. The report highlights significant financial growth, strategic initiatives, and the challenges the company faces in a competitive market. The company continues to focus on innovation and expansion to maintain its market position and meet growing demand for its products.

Financial Highlights

• Revenue: $65,179 million, an increase of 45% in 2025 driven primarily by increased volume, partially offset by lower realized prices.
• Gross Margin: $54,127 million, with gross margin as a percent of revenue increasing to 83.0% in 2025 from 81.3% in 2024, primarily driven by favorable product mix and improved cost of production.
• Operating Income: $25,731 million, a significant increase due to higher gross margin, partially offset by increased marketing, selling, and administrative expenses and research and development expenses.
• Net Income: $20,640 million, an increase of 95% in 2025, primarily due to higher gross margin.
• Diluted EPS: $22.95, reflecting a 96% increase in earnings per share in 2025, driven by strong growth in net income.

Business Highlights

• Revenue Segments: The company operates in a single business segment focused on human pharmaceutical products, with a diverse portfolio including cardiometabolic health, oncology, immunology, and neuroscience products. Key products include Mounjaro, Zepbound, Jardiance, Trulicity, and Verzenio.
• Geographical Performance: The company's products are sold in approximately 90 countries, with manufacturing and distribution facilities in the U.S., Puerto Rico, Europe, and Asia. The U.S. market is significant, with three major wholesale distributors accounting for a substantial portion of revenue.
• Sales Units: Increased volume in 2025, primarily driven by products like Mounjaro and Zepbound, indicating strong market demand and operational performance.
• New Product Launches: Recent approvals include Tirzepatide (Mounjaro, Zepbound) for heart failure and pediatric type 2 diabetes, and Donanemab (Kisunla) for early Alzheimer's disease, expanding the company's therapeutic offerings and market presence.
• New Production Launches: The company is expanding its manufacturing capacity with new sites in North Carolina, Wisconsin, Indiana, Virginia, Texas, Alabama, Pennsylvania, Ireland, Germany, and the Netherlands to support anticipated demand for current and prospective products.
• Future Outlook: The company is focused on discovering and developing innovative medicines, with a robust pipeline of new molecular entities and new indication line extensions in various stages of clinical trials. The company is also navigating regulatory changes and pricing pressures, particularly in the U.S. and international markets.

Strategic Initiatives

• Manufacturing Expansion: Significant initiatives to support anticipated demand for current and prospective products, with additional capacity expected to become operational over the next several years.
• Acquisitions: In 2025, the company acquired Verve Therapeutics, Inc. to enhance its genetic medicines for cardiovascular disease, and acquired a manufacturing site in Wisconsin to expand its global parenteral product manufacturing network. The company also acquired POINT Biopharma Global Inc. to strengthen its capabilities in radiopharmaceutical discovery, development, and manufacturing.
• Capital Management: In 2025, the company repurchased $4.1 billion of shares under its $15.0 billion share repurchase program, with $10.9 billion remaining under this program as of December 31, 2025. Dividends of $6.00 per share were paid in 2025, and the quarterly dividend was increased to $1.73 per share effective for the first quarter of 2026. The company increased its total debt to $42.5 billion as of December 31, 2025, an increase of $8.9 billion compared to the previous year, and maintained $10.1 billion of unused committed bank credit facilities.
• Future Outlook: The company anticipates its near-term financial performance will be impacted by the timing of potential regulatory approvals for new products and U.S. Medicare access for existing products. The company plans to continue its strategic focus on cardiometabolic health products, which are expected to represent a significant and growing portion of its business. Additionally, the company is preparing for potential impacts from U.S. government pricing agreements and international pricing benchmarks, which could influence its pricing strategies and competitive positioning.

Challenges and Risks

• Competitive Market: Eli Lilly operates in a highly competitive pharmaceutical market, facing challenges from multinational pharmaceutical companies, biotechnology firms, and generic drug manufacturers. The company must continuously innovate and develop new products to maintain its market position. The expansion of research and development capabilities in markets like China poses additional competitive pressures.
• Research and Development Risks: Pharmaceutical research and development is costly and uncertain, with a high rate of failure. The company faces risks related to the development, approval, and commercialization of new products. Regulatory hurdles and delays can impact product launches and market opportunities. The company is also exposed to risks from business development activities, including integration challenges and regulatory scrutiny of mergers and acquisitions.
• Revenue Concentration: The company relies heavily on a few key products for a significant portion of its revenue, making it vulnerable to market changes, patent expirations, and competition from generics and biosimilars. Intellectual property protection is critical, and the loss of patent protection can lead to rapid revenue declines.
• Operational Risks: Potential disruptions in the supply chain, manufacturing challenges, and reliance on third-party relationships. Cybersecurity threats and data protection issues pose significant risks to the company's operations and reputation.
• Regulatory Risks: Government price controls and reimbursement restrictions can adversely affect the company's financial results. The company is also subject to evolving tax laws and regulatory compliance challenges, which could result in additional liabilities.
• Market Risks: Exposure to foreign currency exchange rate fluctuations, inflationary pressures, and changes in interest rates. The company is implementing strategies to mitigate these risks, including hedging activities and cost management initiatives.

SEC Filing: ELI LILLY & Co [ LLY ] - 10-K - Feb. 12, 2026